NightstaRx (Nightstar), a fresh spin-out from the University of Oxford, has launched with £12m ($20m) in backing from Syncona, a subsidiary of charity investor the Wellcome Trust. The company is focused on the development and commercialisation of therapies for degenerative conditions which affect vision. The first retinal dystrophy Nightstar will focus on is a gene…
Nightstar welcomes $20m
Jan 30, 2014 •
LEADERSHIP SOCIETYInforming, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
Resistance is futile: seven superconductor companies that want to change the world
From healthcare to fusion to quantum computing to space, superconductors have the potential to revolutionise the world. And the technology is finally ready to commercialise.
UK universities urged to lower spinout stakes
A new report recommends stakes of less than 25% but fails to address the issue of access to early-stage capital.
Dec 14, 2023
Mar 14, 2024
Monterey, CA (USA)
Jun 26, 2024